LSP1 and cancer: Zarling et al. found that phospho-peptides are presented on various types of cancer cells and recognized by CD8+ T cells, indicating that phospho-peptide antigens are potential targets for immunotherapy.[24] Mohammed and coworkers investigated the effect of conformational changes due to phosphorylation on the antigenic identify and concluded that the phospho-peptide neoantigen RQA_V (covering LSP-1 phospho-S251) might be a valuable candidate for cancer immunotherapy [10].